TargetMol

Pemirolast potassium

Product Code:
 
TAR-T1425
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1425-5mg5mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1425-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1425-25mg25mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1425-50mg50mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1425-100mg100mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1425-200mg200mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pemirolast Potassium is the potassium salt form of pemirolast, a pyrimidinone derivative with antiallergic property. Pemirolast potassium exerts its action by blocking the antigen-mediated calcium ion influx into mast cells.
CAS:
100299-08-9
Formula:
C10H7KN6O
Molecular Weight:
266.305
Pathway:
GPCR/G Protein; Neuroscience; Immunology/Inflammation
Purity:
0.9989
SMILES:
[K+].Cc1cccn2c1ncc(-c1nnn[n-]1)c2=O
Target:
Histamine Receptor

References

1. Kemp JP, et al. Ann Allergy, 1992, 68(6), 488-491. 2. Tatsushima Y, et al. Eur J Pharmacol, 2011, 661(1-3), 57-62. 3. Itoh Y, et al. Neuropharmacology, 2004, 46(6), 888-894. 4. Abelson MB, et al. J Ocul Pharmacol Ther, 2002, 18(5), 475-488.